Eli Lilly (LLY) PT Raised to $250 at Mizuho Securities as Donanemab Granted Breakthrough Therapy Designation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Eli Lilly (LLY) PT Raised to $250 at Mizuho Securities as Donanemab Granted Breakthrough Therapy Designation
June 24, 2021 9:10 AM EDT
Cantor Fitzgerald analyst Louise Chen raised the price target on Eli Lilly (NYSE: LLY) to a "Street High" $300.00 (from $245.00) while maintaining an Overweight rating after the FDA has granted its Alzheimer's disease drug donanemab Breakthrough Therapy Designation.
...
More
June 24, 2021 8:16 AM EDT
Cowen analyst Steve Scala raised the price target on Eli Lilly (NYSE: LLY) to $250.00 (from $235.00) while maintaining an Outperform rating.
The analyst commented, "Earlier this week, FDA released internal memos on regulatory decisions regarding BIIB's aducanumab for AD. Our KOLs conclude they strengthen donanemab... More
June 24, 2021 7:24 AM EDT
Eli Lilly & Co. (NYSE: LLY) 30-day option implied volatility is at 23; compared to its 52-week range of 22 to 46 into receives therapy designation for donanemab from FDA.
...
More
June 24, 2021 7:20 AM EDT
Stocks expected to have increasing option volume: LLY SCS DRI RAD
...
More
June 24, 2021 7:11 AM EDT
Biogen (NASDAQ: BIIB) declines 3.5% after Lilly's (NYSE: LLY) donanemab receives FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
Lilly shares were up 8.3%...
More
June 24, 2021 6:46 AM EDT
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE: LLY) investigational antibody therapy for Alzheimer's disease (AD). The Breakthrough Therapy designation aims to expedite the development and review of drugs that are intended to treat a serious condition when... More
